NewAmsterdam Pharma Company N.V. (NAMS) Stock Price & Analysis
NewAmsterdam Pharma Company N.V. (NAMS) closed at USD 20.62 on Thursday, October 15, 2026, up 3.05% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 20.01; the Oct 15, 2026 session ranged USD 20.21–21.12 on volume of 881,932 shares. Market capitalization is $2.41B, with a 52-week range of USD 19.58–42.21 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/NAMS.md
Key facts (NAMS)
- Analysts: Buy (mean 1.88 on a 1–5 scale) (16 analysts), mean target USD 49.82 (range 38.12–59.45).
- Total return with dividends: 1Y -43.5% vs S&P 500 +18.1%; 5Y +110.6% vs S&P 500 +85.1%.
- Next earnings: 2026-11-04, EPS estimate USD -0.44, revenue estimate $6.4M.
Analysts (NAMS)
Consensus Buy (mean 1.88 on a 1–5 scale), 16 analysts; mean target USD 49.82 (low 38.12, high 59.45).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-05 | RBC Capital | Target lowered | Outperform | $50 → $42 |
| 2026-09-08 | HC Wainwright & Co. | Reiterated | Buy | $52 |
| 2026-08-06 | RBC Capital | Target lowered | Outperform | $51 → $50 |
| 2026-06-30 | RBC Capital | Target raised | Outperform | $47 → $51 |
Total return (dividends reinvested) (NAMS)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -43.5% | +110.6% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -43.6% | +16.0% |
| Volatility (annualized) | 52.5% | 62.5% |
| Max drawdown | -51.7% (Nov 2025→Oct 2026) | -58.9% (Jan 2023→Oct 2023) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 20.62 |
|---|---|
| Change | ▲ 3.05% (up) |
| Previous Close | USD 20.01 |
| Open | USD 20.3 |
| Day Range | USD 20.21 – 21.12 |
| 52-Week Range | USD 19.58 – 42.21 |
| Volume | 881,932 shares |
| Market Cap | $2.41B |
| Exchange | NGM |
Technical Analysis (NAMS)
Nexqual's technical model rates NAMS "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 34.26 (neutral) |
| vs SMA50 | Below (USD 24.39) |
| MACD | -1.07 (negative) |
Analyst Ratings (NAMS)
Wall Street analysts rate NAMS "Buy" based on 16 analysts, with a mean price target of USD 49.82 (range USD 38.12–59.45), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 16 |
| Mean Target | USD 49.82 |
| High Target | USD 59.45 |
| Low Target | USD 38.12 |
| Buy / Hold / Sell | 15 / 1 / 0 |
Earnings (NAMS)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD -0.44 |
| Revenue Estimate | $6.41M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.45 vs est -0.43 ▼ miss |
| 2026-03-31 | USD -0.34 vs est -0.41 ▲ beat |
| 2025-12-31 | USD -0.53 vs est -0.37 ▼ miss |
| 2025-09-30 | USD -0.53 vs est -0.35 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (NAMS)
| Total Revenue | $7.12M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -80.70% |
| Gross Margin | +100.00% |
| Operating Margin | -1752.61% |
| Profit Margin | +0.00% |
| ROE | -36.81% |
| Debt / Equity | 0 |
| Current Ratio | 9.03 |
| Total Cash | $633.85M |
| Total Debt | $82,000 |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (NAMS)
Nexqual rates NewAmsterdam Pharma Company N.V.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Critical — Revenue -56% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $634M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$143M (TTM) |
| Efficiency | Critical — ROE -37%, ROA -20.1% |
Ownership (NAMS)
| Insider Ownership | +0.90% |
|---|---|
| Institutional Ownership | +106.61% |
| Shares Outstanding | 116.90M |
| Float | 81.50M |
| Short % of Float | +18.64% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (NAMS)
NewAmsterdam Pharma Company N.V. is led by Michael Harvey Davidson FACC, Facp. (age 69), CEO, President & Executive Director, per Nexqual as of October 16, 2026 at 05:21 UTC.
| CEO, President & Executive Director | Michael Harvey Davidson FACC, Facp. (age 69) |
|---|---|
| Founder, Chief Scientific Officer, Member of Executive Board & Director | Johannes Jacob Pieter Kastelein FESC (age 71) |
| Chief Financial Officer | Mayur Amrat Somaiya (age 51) |
| Executive Vice President of Sales Enterprise Operations | Chris Deluzio |
| Chief Strategy & Business Officer | Juliette Audet M.B.A., M.Sc. (age 38) |
Major Backers & Investors (NAMS)
Notable institutional backers of NewAmsterdam Pharma Company N.V. include Frazier Life Sciences Management, L.P. , Capital Group, FMR, LLC, according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Frazier Life Sciences Management, L.P. | 15.13% |
| Capital Group | 10.74% |
| FMR, LLC | 8.65% |
| RA Capital Management, L.P. | 7.99% |
| SmallCap World Fund Inc | 7.75% |
| FCPM III Services B.V. | 7.1% |
| Fidelity | 4.69% |
| Deerfield Management Company, L.P | 3.57% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt